Yantai Dongcheng Pharmaceutical Group Co.,Ltd.

Shenzhen Stock Exchange 002675.SZ

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Price to Sales Ratio (P/S) on January 27, 2025: 3.12

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Price to Sales Ratio (P/S) is 3.12 on January 27, 2025, a -16.46% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. 52-week high Price to Sales Ratio (P/S) is 4.01 on March 20, 2024, which is 28.30% above the current Price to Sales Ratio (P/S).
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. 52-week low Price to Sales Ratio (P/S) is 2.86 on July 04, 2024, which is -8.32% below the current Price to Sales Ratio (P/S).
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. average Price to Sales Ratio (P/S) for the last 52 weeks is 3.25.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

Shenzhen Stock Exchange: 002675.SZ

Yantai Dongcheng Pharmaceutical Group Co.,Ltd.

CEO	Mr. Zhi Gang Luo
IPO Date	May 25, 2012
Location	China
Headquarters	No.7 ChangBaiShan Road
Employees	2,333
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Yantai Dongcheng Pharmaceutical Group Co.,Ltd., together with its subsidiaries, engages in the manufacture and sale of biochemical API, chemical medicines, proprietary Chinese medicines, and nuclide drugs products in China. It offers heparin, chondroitin sulphate, and glucosamine series products, as well as collagen, hyaluronic acid, and cytochrome C for use in the therapeutic areas of cardiovascular, oncology, urology, orthopedics, and other therapeutic areas. The company also exports its products to approximately 40 countries and regions, including the Europe, America, Asia Pacific, and internationally. Yantai Dongcheng Pharmaceutical Group Co.,Ltd. was founded in 1998 and is based in Yantai, China.

Key trends

Past 5 years